Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

NCT03080883 PHASE3 COMPLETED Results posted

This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy. Apixaban may help in prevention by blocking some of the enzymes needed for venous thrombosis.

Details

Lead sponsor	Academic and Community Cancer Research United
Phase	PHASE3
Status	COMPLETED
Enrolment	370
Start date	Fri Jul 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cerebral Vein Thrombosis
• Deep Vein Thrombosis
• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Metastatic Malignant Solid Neoplasm
• Pulmonary Embolism
• Splanchnic Vein Thrombosis

Interventions

• Apixaban

Countries

United States